Trial Profile

Early Access Program for TLX250-CDx

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Girentuximab Zr-89 (Primary)
Indications Renal cell carcinoma
Focus Diagnostic use

Most Recent Events

28 Mar 2024 New trial record
25 Mar 2024 According to Telix Pharmaceuticals Limited media release, the first patient has been dosed in its Early access program in Italy for TLX250-CDx

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com